10
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Cardioprotective effects of adenosine transport inhibition during reversible ischaemia in patients with coronary artery disease

, , , , , & show all
Pages 181-186 | Published online: 10 Jul 2009

  • Schlaifer JD, Kerensky RA. Ischemic preconditioning: Clinical relevance and investigative studies. Clin Cardiol 1997; 20: 602-606.
  • Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW, Herrmann HC, Laskey WK. Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Circulation 1990; 82: 2044-2051.
  • Birnbaum Y, Kloner R. Percutaneous transluminal coronary angioplasty as a model of ischemic preconditioning and preconditioning-mimetic drugs. (editorial). J Am Coll Cardiol 1999; 33: 1036-1039.
  • Thorton JD, Liu GS, Olsson RA, Downey JM. Intravenous pre-treatment with A-selective adenosine analogs protects the heart against infarction. Circulation 1991; 84: 350-356.
  • Kerensky RA, Kutcher MA, Braden GA, Applegate RJ, Solis GA, Little WC. The effect of intracoronary adenosine on preconditioning during coronary angioplasty. Clin Cardiol 1995; 18: 91-96.
  • Leesar MA, Stoddard M, Ahmed M, Broadbent J, Bolli R. Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation 1997; 95: 2500-2507.
  • Billinger M, Fleisch M, Eberli M, Garachemani A, Meier B, Seiler C. Is the development of myocardial tolerance to repeated ischemia in humans due to preconditioning or to collateral recruitment? J Am Coll Cardiol 1999; 33: 1027-1035.
  • MacLean DA, Sinoway LI, Leurenberger U. Systemic hypoxia elevates skeletal muscle interstitial adenosine levels in humans. Circulation 1998; 98: 1990-1992.
  • Wohlgelernter D, Cleman M, Highman HA, et al. Regional myocardial dysfunction during coronary angioplasty: evaluation by 2-dimensional echocardiography and 12 lead electrocardiography. J Am Coll Cardiol 1985; 6: 267-274.
  • Pijls NHJ, Van Son JAM, Kirkeeide RL, de Bruyne B, Gould KL. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation 1993; 87: 1354-1376.
  • Belardinelli L, Lerman BB. Adenosine: Cardiac electrophysiology. PACE 1991; 14: 1672-1680.
  • Ely S, Mentzer R, Lasley R, Lee B, Berne R. Functional and metabolic evidence of enhanced myocardial tolerance to ischaemia and reperfusion with adenosine. J Thorac Cardiovasc Surg 1985; 90: 549-556.
  • Deussen A, Stappert M, Schafer S, Kelm M. Quantification of extracellular and intracellular adenosine production. Understanding the transmembranous concentration gradient. Circulation 1999; 99: 2041-2047.
  • Miura T, Ogawa T, Iwamoto T, Shimamoto K, Iimura O. Dipyridamole potentiates the myocardial infarct size-limiting effect of ischemic preconditioning. Circulation 1992; 86: 979-985.
  • McElroy FA, Philp RB. Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterase: possible explanation of mechanism of inhibition of platelet function. Life Sci 1975; 17: 1479-1494.
  • Moncada S, Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978; 1: 1286-1289.
  • Bohm M, Weinhold C, Schwinger RHG, et al. Studies on the nucleoside transporter inhibitor, draflazine, in the human myocardium. Br J Pharm 1994; 112: 137-142.
  • Andersen K, Dellborg M, Swedberg K. Nucleoside transport inhibition by draflazine in unstable coronary disease. Eur J Clin Pharmacol 1996; 51: 7-13.
  • Snoeck E, Ver Donck K, Jacqmin P, et al. Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine. J Pharmacol Exp Ther 1998; 286: 142-149.
  • Itoya M, Miura T, Sakamoto J, Urabe K, Iimura O. Nucleoside transport inhibitors enhance the infarct size-limiting effect of ischemic preconditioning. J Cardiovascular Pharmacol 1994; 24: 846-852.
  • Van Belle H, Verheyen W, Ver Donck K, Janssen PAJ, Robertson JIAS. Prevention of catecholamine-induced cardiac damage and death with a nucleoside transport inhibitor. J Cardiovascul Pharmacol 1992; 20: 173-178.
  • Eltchaninoff H, Cribier A, Tron C, et al. Adaptation to myocardial ischemia during coronary angioplasty demonstrated by clinical, electrocardiographic, echocardiograhpic, and metabolic parameters. Am Heart J 1997; 133: 490-496.
  • Fredholm B, Sollevi A. Cardiovascular effects of adenosine. Clin Physiol 1986; 6: 1-21.
  • Smits P, Straatman C, Pijpers E, Thien T. Dose-dependent inhibition of the hemodynamic response to dipyridamole by caffeine. Clin Pharmacol Ther 1991; 50: 529-537.
  • Böttcher M, Czernin J, Sun KT, Phelps ME, Schelbert HR. Effect of caffeine on myocardial blood flow at rest and during pharmacological vasodilatation. J Nucl Med 1995; 36: 2016-2021.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.